(231 days)
No
The description focuses on inert gas rebreathing and standard hemodynamic calculations, with no mention of AI or ML.
No
The device measures hemodynamic parameters, such as cardiac output and blood pressure, which are diagnostic indicators, not therapeutic interventions.
Yes
The device is indicated for the "determination of a number of hemodynamic parameters," including "Cardiac Output (CO)," "pulmonary blood flow (PBF)," "Arterial Oxygen Saturation," and "Blood Pressures." These measurements are used for assessment and diagnosis of a patient's physiological state.
No
The device description explicitly states "Innocor is a compact point-of-care device" and mentions an "NIBP module option," indicating it includes hardware components beyond just software.
Based on the provided text, the Innocor device is not an In Vitro Diagnostic (IVD).
Here's why:
- IVD Definition: In Vitro Diagnostics are devices intended for use in the collection, preparation, and examination of specimens taken from the human body (such as blood, urine, or tissue) to obtain information for diagnostic purposes.
- Innocor's Function: The Innocor device measures hemodynamic parameters like cardiac output, blood pressure, and oxygen saturation by interacting directly with the patient's respiratory system (inert gas rebreathing) and potentially through a non-invasive blood pressure cuff. It does not analyze specimens taken from the body.
- Method of Measurement: The core technology involves analyzing inhaled and exhaled gases and potentially using a pulse oximeter and blood pressure cuff, all of which are direct measurements on the patient, not analysis of a collected sample.
Therefore, the Innocor device falls under the category of in vivo diagnostic or monitoring devices, not in vitro diagnostics.
N/A
Intended Use / Indications for Use
Innocor is indicated for the determination of a number of hemodynamic parameters.
Cardiac Output (CO) is the principal measured parameter. Utilizing inert gas rebreathing, Innocor measures the relative levels of two inhaled gases of differing blood solubility over approximately 3-4 respirations and calculates pulmonary blood flow (PBF). In the absence of a significant intrapulmonary shunt (arterial oxygen saturation ≤ 95% as measured by a pulse oximeter incorporated in the Innocor), PBF is equal to CC.
As an optional accessory, Innocor includes a noninvasive Blood Pressure (NIBP) monitoring system. This option provides systolic, diastolic and mean arterial pressures.
With the NIBP option, Innocor provides values for the following measured and calculated hemodynamic parameters:
Cardiac Output
Arterial Oxygen Saturation
Heart Rate
Stroke Volume
Lung Volume
Cardiac Index
Stroke Index
Blood Pressures (Systolic, Diastolic, Mean Arterial)
Systemic Vascular Resistance
Systemic Vascular Resistance Index
Product codes (comma separated list FDA assigned to the subject device)
DQK
Device Description
Two Models will be made available initially in the U.S:
Innocor Innocor with NIBP option With the NIBP module option, the device will provide values for the hemodynamic parameters included in the Indications for Use below.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Innocor has been shown by clinical testing to be substantially equivalent in respect to its intended use to measure cardiac output to two predicate technologies: 1) Thermodilution Cardiac Output Computers (American Edwards Laboratories) K872529 and K830892 and 2) the Direct Fick Method preamendment calculation method.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
K970763, K982776, K021138, K032363, K051703
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc)
Not Found
§ 870.1425 Programmable diagnostic computer.
(a)
Identification. A programmable diagnostic computer is a device that can be programmed to compute various physiologic or blood flow parameters based on the output from one or more electrodes, transducers, or measuring devices; this device includes any associated commercially supplied programs.(b)
Classification. Class II (performance standards).
0
K051907 1/2
510(k) Summary
| Applicant | Innovision A/S
Lindvedvej 75
DK-5260 Odense S
Denmark |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Manufacturer | Same |
| Device Name | Innocor™ |
| Common Name | Computer, diagnostic, programmable |
| Classification | Relevant Device Information: Class II
Panel Code: Cardiovascular
Product Code(s): DQK
Regulation: §870.1425 |
| | Innocor has been shown by clinical testing to be substantially
equivalent in respect to its intended use to measure cardiac
output to two predicate technologies: 1) Thermodilution Cardiac
Output Computers (American Edwards Laboratories) K872529
and K830892 and 2) the Direct Fick Method preamendment
calculation method. |
| Summary of Substantial
Equivalence | The pulse oximeter component in the Innocor has been shown to
be substantially equivalent to the
K970763 MTS Option for the ESCORT II Monitor
(Attachment 10A) K982776 Model 9303 Neonatal/Adult Vital Signs
Monitor (See Attachment 2D) K021138 SleepScreen and ApnoeScreen Cardio
(Attachment 10B) |
| | The NIBP component option in the Innocor has been shown to
be substantially equivalent to the K032363 Zoll M-Series (NIBP Option) K051703 Clever TD-3018ATM Blood Pressure Monitor |
| | Innocor is a compact point-of-care device intended to be used
for measurement of a) cardiac output (CO) utilizing inert gas
rebreathing (IGR) technology and b) other hemodynamic
parameters. |
| Device Description | Two Models will be made available initially in the U.S:
Innocor Innocor with NIBP option With the NIBP module option, the device will provide values for
the hemodynamic parameters included in the Indications for Use
below. |
| Intended Use and Indications | Innocor is indicated for the determination of a number of
hemodynamic parameters.
Cardiac Output (CO) is the principal measured parameter.
Utilizing inert gas rebreathing, Innocor measures the relative
levels of two inhaled gases of differing blood solubility over
approximately 3-4 respirations and calculates pulmonary blood
flow (PBF). In the absence of a significant intrapulmonary shunt
(arterial oxygen saturation ≤ 95% as measured by a pulse
oximeter incorporated in the Innocor), PBF is equal to CO.
As an optional accessory, Innocor includes a noninvasive Blood
Pressure (NIBP) monitoring system. This option provides
systolic, diastolic and mean arterial pressures.
With the NIBP option, Innocor provides values for the following
measured and calculated hemodynamic parameters:
Cardiac Output Arterial Oxygen Saturation Heart Rate Stroke Volume Lung Volume Cardiac Index Stroke Index Blood Pressures (Systolic, Diastolic, Mean Arterial) Systemic Vascular Resistance |
1
K051907 2/2
:
:
:
2
Food and Drug Administration
Image /page/2/Picture/2 description: The image shows the seal of the Department of Health and Human Services (HHS) of the United States. The seal features an abstract eagle design with three stylized wing segments, representing the department's mission to protect the health of all Americans and provide essential human services. The words "DEPARTMENT OF HEALTH AND HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle emblem.
9200 Corporate Boulevard Rockville MD 20850
MAR 2 2006
Innovision A/S c/o Mr. Richard O. Wood The Wood Burditt Group 1025 W. Everett Rd, Suite 100 Lake Forest, IL 60045
Re: K051907
Trade Name: Innocor Regulation Number: 21 CFR 870.1425 Regulation Name: Diagnostic Programmable Computer Regulatory Class: Class II (two) Product Code: DQK Dated: July 13, 2005 Received: July 14, 2005
Dear Mr. Wood:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
3
Page 2 - Mr. Richard O. Wood
Please be advised that FDA's issuance of a substantial equivalence determination does not mean I least be advised that i Dri biboadse or our device complies with other requirements of the Act that I DA has made a decormination and Jointinistered by other Federal agencies. You must or any it catal statutes and regulations and limited to: registration and listing (21 Comply with an the Not 81equirements)(1); good manufacturing practice requirements as set CFN Fart 607), labeling (21 CFR Part 800); and if applicable, the electronic forth in the quality systems (Sections 531-542 of the Act); 21 CFR 1000-1050. product laulation control provisions (Declients on a sectibed in your Section 510(k) I mis icter will anow you to organ manxoning of substantial equivalence of your device to a legally prematication. The PDA mining of casification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please If you desire specific advice 10. 900 (240) 276-0120. Also, please note the regulation entitled, Contact the Office of Oomphaller as (21 (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small other general informational and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Bhimma for
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Indications for Use
510(k) Number (if known): K051907
Device Name: Innocor
Indications For Use: Innocor is indicated for the determination of a number of hemodynamic parameters.
Cardiac Output (CO) is the principal measured parameter. Utilizing inert gas rebreathing, Innocor measures the relative levels of two inhaled gases of differing blood solubility over approximately 3-4 respirations and calculates pulmonary blood flow (PBF). In the absence of a significant intrapulmonary shunt (arterial oxygen saturation ≤ 95% as measured by a pulse oximeter incorporated in the Innocor), PBF is equal to CC.
As an optional accessory, Innocor includes a noninvasive Blood Pressure (NIBP) monitoring system. This option provides systolic, diastolic and mean arterial pressures.
With the NIBP option, Innocor provides values for the following measured and calculated hemodynamic parameters:
- Cardiac Output
- Arterial Oxygen Saturation
- Heart Rate
- Stroke Volume
- Lung Volume
- Cardiac Index
- troke Index
- Blood Pressures (Systolic, Diastolic, Mean Arterial)
- ystemic Vascular Resistance
- Systemic Vascular Resistance Index
Prescription Use ਮ (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Division Sign-Off)
Division of Cardiovascular Devices
510(k) Number K051907
Page 1 of 1